2024
Artificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations
Jiao J, Tang H, Sun N, Zhang X. Artificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations. American Journal Of Clinical Pathology 2024, 162: 401-407. PMID: 38716796, DOI: 10.1093/ajcp/aqae053.Peer-Reviewed Original ResearchBanff Working GroupLiver Allograft PathologyBiopsy specimensDonor liversAllograft pathologyAssociated with primary graft dysfunctionMacrovesicular steatosisPrimary graft dysfunctionManual quantificationSteatosis assessmentLiver biopsy specimensSevere macrovesicular steatosisAssessment of liver steatosisGraft dysfunctionPathological evaluationModerate steatosisEvaluate steatosisConsensus recommendationsLiver steatosisSteatosisBanffLiverPathologyAI modelsArtificial intelligence
2023
Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV
Torgersen J, Akers S, Huo Y, Terry J, Carr J, Ruutiainen A, Skanderson M, Levin W, Lim J, Taddei T, So‐Armah K, Bhattacharya D, Rentsch C, Shen L, Carr R, Shinohara R, McClain M, Freiberg M, Justice A, Re V. Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV. Pharmacoepidemiology And Drug Safety 2023, 32: 1121-1130. PMID: 37276449, PMCID: PMC10527049, DOI: 10.1002/pds.5648.Peer-Reviewed Original ResearchConceptsSevere hepatic steatosisHepatic steatosisHIV statusLiver attenuationHounsfield unitsPredictive valueRadiologist assessmentUS Veterans Health AdministrationNoncontrast abdominal CTVeterans Health AdministrationCross-sectional studySample of patientsNegative predictive valueReal-world studyPositive predictive valueAbdominal CTLiver fatTomography scanSteatosisCT imagesHealth AdministrationPharmacoepidemiologic studiesRadiologist reviewHIVPercent agreementDysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat N, Mani A. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients 2023, 15: 2323. PMID: 37242206, PMCID: PMC10222271, DOI: 10.3390/nu15102323.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseHepatocellular carcinomaAlcoholic fatty liver diseaseNonalcoholic fatty liver diseaseInsulin-resistant liverDiet-induced steatosisCurrent therapeutic effortsDysregulation of lipidAccumulation of lipidsHepatic fatPrevalent conditionSevere stagesGenetic predispositionGlucose metabolismHealthcare costsEconomic burdenTherapeutic effortsDiseaseNAFLDCanonical insulinSteatosisLiverCirrhosisSteatohepatitis
2022
Su1365: PANCREATIC STEATOSIS IS NOT ASSOCIATED WITH ADVANCED STAGES OF LIVER FIBROSIS OR GRADE OF STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE
Heymann G, Rahman S, Israel G, Muniraj T. Su1365: PANCREATIC STEATOSIS IS NOT ASSOCIATED WITH ADVANCED STAGES OF LIVER FIBROSIS OR GRADE OF STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE. Gastroenterology 2022, 162: s-573-s-574. DOI: 10.1016/s0016-5085(22)61359-3.Peer-Reviewed Original Research
2021
Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis
González IA, Fuller LD, Zhang X, Papke DJ, Zhao L, Zhang D, Liao X, Liu X, Fiel MI, Zhang X. Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. American Journal Of Clinical Pathology 2021, 157: 434-442. PMID: 34596220, DOI: 10.1093/ajcp/aqab142.Peer-Reviewed Original ResearchConceptsAmiodarone-induced liver injuryAlcoholic steatohepatitisScoring systemLiver injuryTest cohortDifferent histologic featuresHepatocyte ballooning degenerationMallory-Denk bodiesNeutrophilic inflammationHistologic featuresPericellular fibrosisMacrovesicular steatosisBallooning degenerationHistologic differencesLiver parenchymaCohortSteatohepatitisInjuryFurther validationInitial studyZone 1SatellitosisCholestasisSteatosisInflammationCirculating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery
Nakao Y, Amrollahi P, Parthasarathy G, Mauer A, Sehrawat T, Vanderboom P, Nair K, Nakao K, Allen A, Hu T, Malhi H. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine Nanotechnology Biology And Medicine 2021, 36: 102430. PMID: 34174416, PMCID: PMC8418232, DOI: 10.1016/j.nano.2021.102430.Peer-Reviewed Original ResearchConceptsWeight loss surgeryHepatocyte-derived extracellular vesiclesPlasma levelsNAFLD resolutionExtracellular vesiclesWeight loss patientsLogistic regression analysisPlasma extracellular vesiclesNAFLD patientsLipid panelNASH patientsLoss patientsNAFLDInvasive biomarkersPatientsCare testGroup 22EV correlatesSteatosisSurgeryRegression analysisBiomarkersDifferential ultracentrifugationCorrelatesInflammation319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysisApobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2020
Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice
Ghosh S, Yang X, Wang L, Zhang C, Zhao L. Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Computational And Structural Biotechnology Journal 2020, 19: 448-458. PMID: 33510856, PMCID: PMC7806547, DOI: 10.1016/j.csbj.2020.12.011.Peer-Reviewed Original ResearchNon-alcoholic fatty liver diseaseSerum cholesterolGut microbiotaPrebiotic feedingLiver steatosisHepatic steatosisHigh fat diet fed miceHigh-fat diet-fed miceAlters gut microbiotaDiet fed miceFatty liver diseaseDiet-fed miceCholesterol-lowering effectGut microbiota structureImpact of prebioticsIncreased SCFA productionPrebiotic intakeLiver diseaseFed micePrebiotic consumptionDay 7SteatosisBeneficial effectsWeight lossUnrestricted feedingHepatocellular neoplasms arising in genetic metabolic disorders: steatosis is common in both the tumor and background liver
Cheng L, Jain D, Kakar S, Torbenson MS, Wu TT, Yeh MM. Hepatocellular neoplasms arising in genetic metabolic disorders: steatosis is common in both the tumor and background liver. Human Pathology 2020, 108: 93-99. PMID: 33245984, DOI: 10.1016/j.humpath.2020.11.012.Peer-Reviewed Original ResearchConceptsGenetic metabolic disordersMetabolic disordersHepatocellular neoplasmsBackground liverType 1Ornithine carbamyl transferase deficiencyRare genetic metabolic disorderRare case reportBackground liver parenchymaGlycogen storage disease type 1Hereditary tyrosinemia type 1Disease type 1Tyrosinemia type 1Younger patientsRetrospective studyCase reportCommon findingLiver parenchymaSteatosisTransferase deficiencyPathological characterizationNeoplasmsTumorsDisordersPatientsMembrane-bound sn-1,2-diacylglycerols explain the dissociation of hepatic insulin resistance from hepatic steatosis in MTTP knockout mice
Abulizi A, Vatner DF, Ye Z, Wang Y, Camporez JP, Zhang D, Kahn M, Lyu K, Sirwi A, Cline GW, Hussain MM, Aspichueta P, Samuel VT, Shulman GI. Membrane-bound sn-1,2-diacylglycerols explain the dissociation of hepatic insulin resistance from hepatic steatosis in MTTP knockout mice. Journal Of Lipid Research 2020, 61: 1565-1576. PMID: 32907986, PMCID: PMC7707176, DOI: 10.1194/jlr.ra119000586.Peer-Reviewed Original ResearchConceptsHepatic insulin resistanceInsulin resistanceHepatic insulin sensitivityHepatic steatosisLipid-induced hepatic insulin resistancePKCε activationInsulin sensitivityKnockout miceNormal hepatic insulin sensitivityWild-type control miceHepatic ceramide contentHyperinsulinemic-euglycemic clampComprehensive metabolic phenotypingLipid dropletsHepatic DAG contentDAG contentGlucose intoleranceControl miceMTTP activityHepatic insulinAnimal modelsSteatosisAKT Ser/ThrMiceMetabolic phenotypingNIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease
Li Y, Chen M, Zhou Y, Tang C, Zhang W, Zhong Y, Chen Y, Zhou H, Sheng L. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. Theranostics 2020, 10: 3579-3593. PMID: 32206109, PMCID: PMC7069072, DOI: 10.7150/thno.40149.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsEthanolFatty AcidsFatty LiverHepatocytesInflammationLiver Diseases, AlcoholicMaleMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMice, Inbred C57BLMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Oxidation-ReductionPhosphorylationPPAR alphaProtein Serine-Threonine KinasesSignal TransductionConceptsAlcoholic liver diseaseFatty acid oxidationAlcoholic steatosisHepatic fatty acid oxidationHepatocyte-specific deletionHepatic steatosisLiver diseasePPARα agonistAcid oxidationBinge ethanol feedingMain pathological featuresHepatic lipid accumulationEthanol-fed miceRegulation of PPARαRole of NIKALD therapyInflammatory cytokinesPathological featuresUnderlying pathogenesisPharmacological interventionsSteatosisEthanol feedingInflammationPharmacological inhibitionPPARα
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplicationsGlutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis
Choi W, Kim H, Kim M, Cinar R, Yi H, Eun H, Kim S, Choi Y, Lee Y, Kim S, Seo W, Lee J, Shim Y, Kim Y, Yang K, Ryu T, Hwang J, Lee C, Choi H, Gao B, Kim W, Kim S, Kunos G, Jeong W. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metabolism 2019, 30: 877-889.e7. PMID: 31474565, PMCID: PMC6834910, DOI: 10.1016/j.cmet.2019.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmino Acid Transport System y+AnimalsArachidonic AcidsEndocannabinoidsFatty Liver, AlcoholicFemaleGlutamic AcidGlyceridesHEK293 CellsHep G2 CellsHepatic Stellate CellsHepatocytesHumansLipogenesisMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedReceptor, Cannabinoid, CB1Receptor, Metabotropic Glutamate 5Signal TransductionTransfectionConceptsAlcoholic liver diseaseExpression of metabotropic glutamate receptor 5Pharmacological inhibition of mGluR5Metabotropic glutamate receptor 5Alcoholic steatosisCannabinoid receptor 1Glutamate receptor 5Inhibition of mGluR5Extracellular glutamate levelsGlutamate signalingGlutamate levelsHepatic stellate cellsMGluR5Receptor 5Receptor 1Liver diseaseMetabolic synapsePharmacological inhibitionStellate cellsCystine uptakeCompensatory increaseCysteine deficiencyGlutathione depletionSteatosisMiceAdipose glucocorticoid action influences whole‐body metabolism via modulation of hepatic insulin action
Abulizi A, Camporez JP, Jurczak MJ, Høyer KF, Zhang D, Cline GW, Samuel VT, Shulman GI, Vatner DF. Adipose glucocorticoid action influences whole‐body metabolism via modulation of hepatic insulin action. The FASEB Journal 2019, 33: 8174-8185. PMID: 30922125, PMCID: PMC6593882, DOI: 10.1096/fj.201802706r.Peer-Reviewed Original ResearchConceptsWhole-body metabolismHepatic insulin actionHepatic insulin resistanceGlucocorticoid actionHepatic steatosisHepatic glycogen synthesisInsulin resistanceAdipose lipolysisFood intakeInsulin actionAdipose triglyceride lipase expressionGlucose-dependent organsReceptor knockout miceOral glucose challengeHepatic lipid accumulationHigh-fat dietHyperinsulinemic-euglycemic conditionsGlycogen synthesisProtein kinase B phosphorylationInsulin responseGlucose challengeHepatic insulin responseHepatic insulinMetabolic cagesSteatosisChapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications
Galderisi A, Martino M, Santoro N. Chapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications. 2019, 91-99. DOI: 10.1016/b978-0-323-55138-0.00011-5.BooksNonalcoholic fatty liver diseaseFatty liver diseaseType 2 diabetesLiver diseasePediatric nonalcoholic fatty liver diseasePathophysiology of NAFLDEnd-stage liver diseaseIndependent risk factorPathophysiologic linkCommon complicationSimple steatosisPediatric obesityInsulin resistanceRisk factorsType 2Disease severityDiseaseDiabetesWide spectrumComplicationsPotential implicationsSteatosisObesityPathophysiologySeverity
2017
Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans
Horst K, Gilijamse PW, Versteeg RI, Ackermans MT, Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ. Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. Cell Reports 2017, 19: 1997-2004. PMID: 28591572, PMCID: PMC5469939, DOI: 10.1016/j.celrep.2017.05.035.Peer-Reviewed Original ResearchConceptsHepatic insulin resistanceInsulin resistanceHepatic steatosisObese subjectsPKCε activationTissue-specific insulin sensitivityHepatic ceramide contentPeripheral insulin resistanceHepatic lipid accumulationPathogenesis of NAFLDLiver biopsyIntrahepatic triglyceridesLiver fatInsulin sensitivityAdipose tissueTranslational evidenceSteatosisLipid accumulationCeramide contentPKCε translocationSubjectsMolecular mechanismsDiacylglycerol contentHumansActivation
2016
Chronic Glutathione Depletion Confers Protection against Alcohol-induced Steatosis: Implication for Redox Activation of AMP-activated Protein Kinase Pathway
Chen Y, Singh S, Matsumoto A, Manna SK, Abdelmegeed MA, Golla S, Murphy RC, Dong H, Song BJ, Gonzalez FJ, Thompson DC, Vasiliou V. Chronic Glutathione Depletion Confers Protection against Alcohol-induced Steatosis: Implication for Redox Activation of AMP-activated Protein Kinase Pathway. Scientific Reports 2016, 6: 29743. PMID: 27403993, PMCID: PMC4940737, DOI: 10.1038/srep29743.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseGclm KO miceLiver steatosisKO miceAlcohol-induced liver steatosisFactor 2 (Nrf2) target genesEthanol-containing liquid dietOxidative stressGclm knockout mouseAlcohol-induced steatosisHepatic lipid profilesProtein kinase pathwayNew therapeutic strategiesNormal hepatic levelsLevels of glutathioneFatty acid oxidationKinase pathwayLiver diseaseLipid profileLiquid dietEthanol clearanceHepatic levelsTherapeutic strategiesKnockout miceSteatosisThe Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Herman MA, Samuel VT. The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis. Trends In Endocrinology And Metabolism 2016, 27: 719-730. PMID: 27387598, PMCID: PMC5035631, DOI: 10.1016/j.tem.2016.06.005.Peer-Reviewed Original ResearchConceptsFructose consumptionHepatic fructose metabolismHepatic insulin resistanceImpairment of insulinDe novo lipogenesisHepatic steatosisInsulin resistanceEpidemiological studiesNovo lipogenesisMetabolic diseasesFructose metabolismLipogenic enzymesLipogenesisFatty acid synthesisKey transcription factorDiseaseAldolase BLipid synthesisAdditional mechanismHypertriglyceridemiaSteatosisTranscription factorsTherapyInsulinImpairment
2014
Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation
Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan DC, Silva AM, Rakela J, Vargas HE. Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdominal Radiology 2014, 40: 795-802. PMID: 25445158, DOI: 10.1007/s00261-014-0310-y.Peer-Reviewed Original ResearchConceptsLive liver donationLiver biopsyLiver donationMagnetic resonance elastographyHepatic steatosisOptimal cutoffExact testPotential live liver donorsAbnormal liver biopsyAbnormal liver histologyLive liver donorsDegree of steatosisDonor evaluation processLiver biopsy resultsROC curveFisher's exact testLiver shear stiffnessAbility of MREResonance elastographyLiver histologyBiopsy resultsLiver donorsLiver fibrosisSteatosisBiopsy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply